- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| FLUOGUIDE Aktie jetzt für 0€ handeln | |||||
| 01.07. | FluoGuide A/S: Update on 2026 Outlook and Company Progress | 309 | ACCESS Newswire | COPENHAGEN, DK / ACCESS Newswire / July 1, 2026 / FluoGuide A/S ("FluoGuide" or the "Company")(STO:FLUO), a clinical-stage biotech company focused on precision cancer surgery, is pleased to share an... ► Artikel lesen | |
| 29.06. | FluoGuide A/S: FluoGuide Announces Positive Results from Phase 2 Oral, Head and Neck Cancer Trial | 322 | ACCESS Newswire | COPENHAGEN, DK / ACCESS Newswire / June 29, 2026 / FluoGuide A/S ("FluoGuide" or the "Company") (STO:FLUO), a biotech company maximizing surgical outcomes in oncology by lighting up cancer, today announced... ► Artikel lesen | |
| 27.05. | FluoGuide A/S Publishes Interim Report for Q1 2026 | 359 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / May 27, 2026 / Fluoguide A/S (STO:FLUO) ("FluoGuide" or the "Company") today releases its results for the period 1 January 2026 - 31 March 2026. The Q1 report is available... ► Artikel lesen | |
| 13.05. | Invitation to FluoGuide A/S Live Webcast on 27 May 2026 | 294 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / May 13, 2026 / FluoGuide A/S (STO:FLUO) will publish its interim report for Q1 2026 on Wednesday, 27 May 2026.Later that day, CEO Morten Albrechtsen and CFO Ole Larsen... ► Artikel lesen | |
| 10.04. | FluoGuide A/S: Positive interim results from an investigator-initiated study of FG001 in meningioma and low-grade glioma surgery, re-presented at SNOG | 175 | GlobeNewswire (Europe) | Copenhagen, Denmark, 10 April 2026 - FluoGuide A/S ("FluoGuide" or the "Company"), a clinical-stage biotech company maximizing surgical outcomes in oncology by lighting up cancer.
The interim data from... ► Artikel lesen | |
| 25.03. | Minutes from Annual General Meeting in FluoGuide A/S | 398 | ACCESS Newswire | COPENHAGEN, DENMARK / ACCESS Newswire / March 25, 2026 / FluoGuide A/S (STO:FLUO)("FluoGuide" or the "Company") held its annual general meeting on 25 March 2026.To the shareholders of FluoGuide A/S.The... ► Artikel lesen | |
| 18.03. | FluoGuide A/S: FluoGuide Receives FDA Fast Track Designation for FG001 in High-Grade Glioma | 333 | ACCESS Newswire | COPENHAGEN, DENMARK / ACCESS Newswire / March 18, 2026 / FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company"), a biotech company maximizing surgical outcomes in oncology by lighting up cancer, announces... ► Artikel lesen | |
| 10.03. | Notice of Annual General Meeting in FluoGuide A/S | 460 | ACCESS Newswire | KØBENHAVN, DENMARK / ACCESS Newswire / March 10, 2026 / FluoGuide A/S (STO:FLUO)The board of directors hereby convenes the Annual General Meeting of FluoGuide A/S, company registration (CVR) no. 39... ► Artikel lesen | |
| 25.02. | FluoGuide A/S Publishes Annual Report For The Fiscal Year 2025 | 522 | ACCESS Newswire | COPENHAGEN, DK / ACCESS Newswire / February 25, 2026 / FluoGuide A/S ("FluoGuide" or the "Company")(STO:FLUO) hereby publishes its annual report for the fiscal year 2025. The annual report, including... ► Artikel lesen | |
| 25.02. | FluoGuide A/S Publishes Interim Report For Q4 2025 | 345 | ACCESS Newswire | COPENHAGEN, DK / ACCESS Newswire / February 25, 2026 / Fluoguide A/S ("FluoGuide" or the "Company")(STO:FLUO) today releases its results for the period 1 January 2025 - 31 December 2025. The Q4 report... ► Artikel lesen | |
| 20.02. | FluoGuide A/S: FDA Clears FluoGuide's IND for FG001 in High-Grade Glioma; U.S. Clinical Trial Remains on Track | 700 | ACCESS Newswire | COPENHAGEN, DENMARK / ACCESS Newswire / February 20, 2026 / FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company"), a biotech company maximizing surgical outcomes in oncology by lighting up cancer... ► Artikel lesen | |
| 19.02. | Invitation to FluoGuide A/S Live Webcast on 25 February 2026 | 278 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / February 19, 2026 / FluoGuide A/S (STO:FLUO) will publish its Annual Report 2025 on Wednesday, 25 February 2026.Later that day, CEO Morten Albrechtsen and CFO Ole Larsen... ► Artikel lesen | |
| 21.01. | FluoGuide A/S: FluoGuide Submits an IND for FG001, to Initiate First U.S. Registration Trial | 327 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / January 21, 2026 / FluoGuide A/S ("FluoGuide" or the "Company")(STO:FLUO), a biotech company maximizing surgical outcomes in oncology by lighting up cancer, today announced... ► Artikel lesen | |
| 27.11.25 | FluoGuide A/S Publishes Interim Report Q3 2025 | 430 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / November 27, 2025 / FluoGuide A/S ("FluoGuide" or the "Company") (STO:FLUO) today releases its results for the period 1 January - 30 September 2025. The Q3 report is... ► Artikel lesen | |
| 25.11.25 | FluoGuide A/S: FluoGuide Signs Collaboration Agreement with ZEISS | 451 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / November 25, 2025 / FluoGuide A/S (STO:FLUO) - Copenhagen, Denmark, 25 November 2025 - FluoGuide A/S, a biotech company specializing in precision cancer surgery, announces... ► Artikel lesen | |
| 24.11.25 | Minutes from Extraordinary General Meeting in FluoGuide A/S | 369 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / November 24, 2025 / FluoGuide A/S (STO:FLUO)("FluoGuide" or the "Company" held an extraordinary general meeting on 24 November 2025.To the shareholders of FluoGuide... ► Artikel lesen | |
| 24.11.25 | Invitation to FluoGuide A/S Webcast on 27 November 2025 | 366 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / November 24, 2025 / FluoGuide A/S (STO:FLUO) - FluoGuide A/S will publish its Interim Report Q3 2025 on Thursday 27 November 2025.The following event will take place... ► Artikel lesen | |
| 05.11.25 | FluoGuide A/S: FluoGuide Strengthens Leadership to Advance Clinical Program and Regulatory Approval Strategy | 433 | ACCESS Newswire | KØBENHAVN, DK / ACCESS Newswire / November 5, 2025 / FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company"), a biotech company specializing in precision cancer surgery, announces changes to both its... ► Artikel lesen | |
| 05.11.25 | FluoGuide A/S: FluoGuide Convenes an Extraordinary General Meeting | 372 | ACCESS Newswire | COPENHAGEN, DENMARK / ACCESS Newswire / November 5, 2025 / FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company") hereby invites shareholders to participate in an extraordinary general meeting to be... ► Artikel lesen | |
| 03.11.25 | FluoGuide A/S Issue Warrants to Board Members, Executive Management and Employees | 405 | ACCESS Newswire | COPENHAGEN, DENMARK / ACCESS Newswire / November 3, 2025 / FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company") announces that it has issued 199,000 warrants to members of the board directors, members... ► Artikel lesen |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ADVANCED BIOMED | 9,000 | +1,12 % | Morning Market Movers: Baiya International Group, Globavend, Advanced Biomed, Sadot Group See Big Swings | CANBERA (dpa-AFX) - At 7:25 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 70,54 | +0,06 % | S&P Dow Jones Indices: BrightSpring Health Services Set to Join S&P MidCap 400 and Karman Holdings to Join S&P SmallCap 600 | NEW YORK, July 14, 2026 /PRNewswire/ -- S&P SmallCap 600 constituent BrightSpring Health Services Inc. (NASD: BTSG) will replace Chart Industries Inc. (NYSE: GTLS)... ► Artikel lesen | |
| PRIVIA HEALTH GROUP | 26,260 | 0,00 % | Privia Health Group, Inc.: Privia Health Reports First Quarter 2026 Financial Results | Strong First Quarter Performance and Operating ExecutionReiterated Full-Year 2026 Guidance Reflects Continued Momentum ARLINGTON, Va., May 07, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq:... ► Artikel lesen | |
| LIFESTANCE HEALTH GROUP | 11,340 | 0,00 % | LifeStance Health Group, Inc.: LifeStance Reports First Quarter 2026 Results | SCOTTSDALE, Ariz., May 07, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation's largest providers of outpatient mental healthcare, today announced financial results... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 21,090 | -0,05 % | Reasons to Retain Alignment Healthcare Stock in Your Portfolio for Now | ||
| FRESENIUS MEDICAL CARE | 42,820 | +1,23 % | FMC: Analysten sehen Abwärtspotenzial | Am 4. August wird Fresenius Medical Care, kurz FMC, die Zahlen zum zweiten Quartal vorstellen. Die Analysten der Deutschen Bank rechnen mit einem organischen Umsatzplus von 3 Prozent. Deutlicher soll... ► Artikel lesen | |
| FRESENIUS | 43,270 | +1,36 % | Fresenius: Hoffnungen auf Prognoseanhebung und Kurssprung | Fresenius steht möglicherweise vor einer Anhebung seiner Jahresprognose, nachdem Analysten ein starkes zweites Quartal erwarten. Die Deutsche Bank sieht weiteres Kurspotenzial und hält trotz bereits... ► Artikel lesen | |
| BILLIONTOONE | 125,20 | +0,05 % | BillionToOne Appoints Ethan Dmitrovsky, MD, as Chief Medical Officer, Oncology, to Lead Medical Strategy for Northstar | Renowned physician-scientist, former Director of Frederick National Laboratory, and one of the nation's most accomplished leaders in oncology joins BillionToOne... ► Artikel lesen | |
| GENEDX | 60,73 | +0,13 % | Piper Sandler raises GeneDx stock price target on coverage policy | ||
| SIEMENS HEALTHINEERS | 34,620 | -1,59 % | ANALYSE-FLASH: UBS belässt Siemens Healthineers auf 'Neutral' - Ziel 38 Euro | ZÜRICH (dpa-AFX Broker) - Die Schweizer Großbank UBS hat die Einstufung für Siemens Healthineers mit einem Kursziel von 38 Euro auf "Neutral" belassen. In der Radiotherapie heiße es nicht mehr nur... ► Artikel lesen | |
| AVEANNA HEALTHCARE | 9,690 | 0,00 % | Aveanna Healthcare (AVAH): Best Future Stocks to Buy Under $10 | ||
| CARL ZEISS MEDITEC | 27,860 | -3,06 % | Carl Zeiss Meditec, Jost Werke: frische Shortpositionen - bei Deutz wie Symrise Fonds auf Rückzug | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert, unterliegt Transparenzpflichten gemäß EU-Leerverkaufsverordnung. Ab einer Netto-Leerverkaufsposition von 0,5 Prozent des ausgegebenen Aktienkapitals... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 19,220 | 0,00 % | PROCEPT BioRobotics to Report Second Quarter 2026 Financial Results on August 4th, 2026 | ||
| PROGYNY | 31,750 | -0,06 % | KeyBanc raises Progyny stock price target on utilization strength | ||
| HEARTFLOW | 24,540 | -0,08 % | Stifel reiterates HeartFlow stock rating after cardiology meeting |
FLUOGUIDE A/S gehört der Branche Gesundheitswesen an. Die relative Kursveränderung beträgt aktuell -2,17 % bei einem Aktienkurs von 2,700 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FLUOGUIDE A/S finden Sie auf Wallstreet Online.